TY - JOUR
T1 - Can the mean linear energy transfer of organs be directly related to patient toxicities for current head and neck cancer intensity-modulated proton therapy practice?
AU - Wagenaar, Dirk
AU - Schuit, Ewoud
AU - van der Schaaf, Arjen
AU - Langendijk, Johannes A
AU - Both, Stefan
N1 - Funding Information:
We would like to acknowledge the contributions of Gijs Katgert, Nísia Santos Fernandez and Chioma Onyia towards gathering the required data.
Publisher Copyright:
© 2021 The Authors
PY - 2021/12
Y1 - 2021/12
N2 - BACKGROUND AND PURPOSE: The relative biological effectiveness (RBE) of proton therapy is predicted to vary with the dose-weighted average linear energy transfer (LETd). However, RBE values may substantially vary for different clinical endpoints. Therefore, the aim of this study was to assess the feasibility of relating mean D⋅LETd parameters to patient toxicity for HNC patients treated with proton therapy.MATERIALS AND METHODS: The delivered physical dose (D) and the voxel-wise product of D and LETd (D⋅LETd) distributions were calculated for 100 head and neck cancer (HNC) proton therapy patients using our TPS (Raystation v6R). The means and covariance matrix of the accumulated D and D⋅LETd of all relevant organs-at-risk (OARs) were used to simulate 2.500 data sets of different sizes. For each dataset, an attempt was made to add mean D⋅LETd parameters to a multivariable NTCP model based on mean D parameters of the same OAR for xerostomia, tube feeding and dysphagia. The likelihood of creating an NTCP model with statistically significant parameters (i.e. power) was calculated as a function of the simulated sample size for various RBE models.RESULTS: The sample size required to have a power of at least 80% to show an independent effect of mean D⋅LETd parameters on toxicity is over 15,000 patients for all toxicities.CONCLUSION: For current clinical practice, it is not feasible to directly model NTCP with both mean D and mean D⋅LETd of OARs. These findings should not be interpreted as a contradiction of previous evidence for the relationship between RBE and LETd.
AB - BACKGROUND AND PURPOSE: The relative biological effectiveness (RBE) of proton therapy is predicted to vary with the dose-weighted average linear energy transfer (LETd). However, RBE values may substantially vary for different clinical endpoints. Therefore, the aim of this study was to assess the feasibility of relating mean D⋅LETd parameters to patient toxicity for HNC patients treated with proton therapy.MATERIALS AND METHODS: The delivered physical dose (D) and the voxel-wise product of D and LETd (D⋅LETd) distributions were calculated for 100 head and neck cancer (HNC) proton therapy patients using our TPS (Raystation v6R). The means and covariance matrix of the accumulated D and D⋅LETd of all relevant organs-at-risk (OARs) were used to simulate 2.500 data sets of different sizes. For each dataset, an attempt was made to add mean D⋅LETd parameters to a multivariable NTCP model based on mean D parameters of the same OAR for xerostomia, tube feeding and dysphagia. The likelihood of creating an NTCP model with statistically significant parameters (i.e. power) was calculated as a function of the simulated sample size for various RBE models.RESULTS: The sample size required to have a power of at least 80% to show an independent effect of mean D⋅LETd parameters on toxicity is over 15,000 patients for all toxicities.CONCLUSION: For current clinical practice, it is not feasible to directly model NTCP with both mean D and mean D⋅LETd of OARs. These findings should not be interpreted as a contradiction of previous evidence for the relationship between RBE and LETd.
KW - Biological modeling
KW - Head and neck tumors
KW - LET
KW - Linear energy transfer
KW - NTCP modeling
KW - Proton beam therapy
KW - RBE
KW - Relative biological effectiveness
UR - https://www.scopus.com/pages/publications/85119071366
U2 - 10.1016/j.radonc.2021.09.003
DO - 10.1016/j.radonc.2021.09.003
M3 - Article
C2 - 34534614
SN - 0167-8140
VL - 165
SP - 159
EP - 165
JO - Radiotherapy & Oncology
JF - Radiotherapy & Oncology
IS - 12
ER -